ICH Q and A demystifies periodic benefit-risk evaluation reporting
This article was originally published in SRA
Executive Summary
The International Conference on Harmonisation has issued a new Q&A document to clarify the guideline it finalized in November 2012 on periodic benefit-risk evaluation reporting (PBRER) on marketed medicines1,2.